冠状动脉疾病和心力衰竭患者的肥胖管理
Akheel A Syed1, Safwaan Adam2, Christopher A Miller3
1Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, Manchester M13 9PL, UK; Department of Diabetes, Endocrinology & Obesity Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Stott Lane, Salford M6 8HD, UK.
Heart failure clinics
|March 19, 2025
概括
肥胖通过直接影响和糖尿病和高血压等危险因素使心脏病恶化. 包括药物和减肥手术在内的减肥干预措施对于管理与肥胖有关的心脏病至关重要.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖是心血管疾病的重要危险因素,有助于诸如高血压,失脂症和2型糖尿病等疾病.
- 肥胖的不良病理生理变化直接影响心脏功能,导致诸如肥胖相关心肌病症等疾病.
- 与肥胖相关的趋同风险因素加剧了它对心血管健康的有害影响.
研究的目的:
- 审查肥胖和心脏病之间的因果关系.
- 讨论减肥干预措施在管理与肥胖有关的心肌病的作用.
- 评估抗肥胖药物和减肥手术在肥胖和心力衰竭患者的治疗潜力.
主要方法:
- 对调查肥胖和心血管结果之间的关系的研究进行文献综述.
- 对与肥胖有关的心脏病减肥策略的现有证据的分析.
- 对肥胖和心力衰竭的药理和手术干预措施的评估.
主要成果:
- 肥胖直接和间接地导致心脏病的发展和进展.
- 减肥是肥胖相关心肌病的关键治疗策略.
- -葡萄糖共传输体-2 抑制剂和类似葡萄糖的1受体激动剂在治疗肥胖和心力衰竭方面表现有前途.
- 腹腔外科手术是冠状动脉疾病和心力衰竭的严重肥胖的可行选择,需要谨慎管理.
结论:
- 有效的肥胖管理对于预防和治疗心脏病至关重要.
- 药理和手术干预为肥胖和心力衰竭患者提供了重要的治疗途径.
- 个性化的患者选择和全面的管理对于心脏病患者的成功减肥手术结果至关重要.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:24Obesity
356
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
356
01:22Heart Failure Drugs: Diuretics
312
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
312
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K